Potential Breakthrough Treatment For Enlarged Prostate

A potential breakthrough treatment for patients with an enlarged prostate is attracting attention as studies begin to show a new interventional technique could be a very effective alternative to surgery. A minimally invasive procedure known as prostate artery embolization was one of the main subjects of an interventional radiology conference, where results of a study were recently released.

In what is being described as a breakthrough treatment option for patients with benign prostatic hyperplasia (BPH), researchers are studying the use of an interventional radiology treatment known as prostate artery embolization (PAE). Officials at the Society of Interventional Radiology (SIR) say PAE is a more effective minimally invasive treatment for BPH that is less invasive and has fewer complications than other options such as transurethral resection of the prostate. BPH, also referred to as an enlarged prostate, affects more than 50% of men 60 years and older in the US and more than 80% of men 80 years and older. (SeeAlso see "BPH: An Expanding Opportunity" - Medtech Insight, 1 September, 2008..)

News and data from the study were released at SIR’s 40th Annual Scientific Meeting, held from February 28 to March...

More from Clinical Trials

Novel Pathway For Combined Drug/IVD Trials Wins Backing Of EU Nations

 
• By 

Broad participation by EU member states in a new pilot to test a unified procedure for evaluating applications for combined drug and IVD studies shows they recognize its value, says Monique Al, vice-chair of the Clinical Trials Coordination Group.

‘Be Quick, But Don’t Hurry’: Dexcom CEO Talks CGM Market Success

 
• By 

Dexcom’s CEO Kevin Sayer discusses this fall’s planned launch of the 15-day G7 CGM, downplays Abbott’s dual-sensor while focusing on development of multi-analyte G8, making OTC Stelo app more “consumerish” for Europeans, and more.

European Commission Asks For ‘Open Minds’ On Unified Drug/Device Research Pathway

 
• By 

As the EU tests the feasibility of a radical “all-in-one” procedure for combined drug and IVD studies, sponsors are being urged to approach this novel framework with flexibility and openness.

No Strings Attached: Big Players Chase Insulet In Fast-Growing Tubeless Insulin Pump Market

 
• By 

Medtronic, Tandem and Beta Bionics are gearing up to bring tubeless patch pumps to market, chasing Insulet’s Omnipod 5, the only FDA-cleared patch pump for type 1 and type 2 diabetes. Analysts expect tubeless models to eventually displace durable pumps.

More from R&D

European Commission Asks For ‘Open Minds’ On Unified Drug/Device Research Pathway

 
• By 

As the EU tests the feasibility of a radical “all-in-one” procedure for combined drug and IVD studies, sponsors are being urged to approach this novel framework with flexibility and openness.

No Strings Attached: Big Players Chase Insulet In Fast-Growing Tubeless Insulin Pump Market

 
• By 

Medtronic, Tandem and Beta Bionics are gearing up to bring tubeless patch pumps to market, chasing Insulet’s Omnipod 5, the only FDA-cleared patch pump for type 1 and type 2 diabetes. Analysts expect tubeless models to eventually displace durable pumps.

UK Center To Develop Brain Stimulation Devices Opens

 

Backed by £50m of UK government funding, the new research center will delve into neural dynamics to develop novel devices ranging from brain implants to wearables.